Clinical significance of telomerase activity in multiple myeloma

Cancer

Volumn 94, Issue 8, 2002, Pages 2232-2238

  Shiratsuchi, Motoaki ^a,b   Muta, Koichiro ^a   Abe, Yasunobu ^a   Motomura, Seiichi ^b   Taguchi, Fumihiro ^c   Takatsuki, Hiroshi ^d   Uike, Naokuni ^d   Umemura, Tsukuru ^b   Nawata, Hajime ^a   Nishimura, Junji ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c ASO IIZUKA HOSPITAL   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

Author keywords

2 microglobulin; Ki 67; Multiple myeloma; Prognostic factor; Telomerase activity

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; CD38 ANTIGEN; CD45 ANTIGEN; CREATININE; KI 67 ANTIGEN; LACTATE DEHYDROGENASE; TELOMERASE; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CELL KINETICS; CELL PROLIFERATION; CELL SUBPOPULATION; CLINICAL ARTICLE; DISEASE COURSE; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIPLE MYELOMA; MYELOMA CELL; PLASMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BETA 2-MICROGLOBULIN; C-REACTIVE PROTEIN; CREATININE; FEMALE; HUMANS; KI-67 ANTIGEN; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TELOMERASE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0037089647     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10472     Document Type: Article

References (25)

1. Multiple myeloma
2. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma
3. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma
4. Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma
5. Evaluation of serum thymidine kinase as a marker in multiple myeloma
6. Prognostic factors in multiple myeloma
7. Renal function in newly diagnosed multiple myeloma- a demographic study of 1353 patients
8. Serum β2-microglobulin and survival duration in multiple myeloma: A simple, reliable marker for staging
9. Acute phase proteins and prognosis in multiple myeloma
10. High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma
11. Prognostic factors and staging in multiple myeloma: A reappraisal
12. Telomere length, aging, and somatic cell turnover
13. Telomerase activity in normal leukocytes and in hematologic malignancies
14. Specific association of human telomerase activity with immortal cells and cancer
15. Telomerase activity as a prognostic indicator in stage I non- small cell lung cancer
16. Telomerase activity in gastric cancer
17. Telomerase activity in myeloma cells is closely related to cell cycle status, but not to apoptotic signals induced by interferon-α
18. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
19. Prognostic factors in myeloma: What they tell us about the pathophysiology of the disease
20. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67
21. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer
22. Prognostic value of pretreatment serum β2 microglobulin in myeloma: A Southwest Oncology Group Study
23. Value of β2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma
24. Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and Creactive protein in multiple myeloma
25. Telomere lengthening and telomerase activation during human B cell differentiation